196 related articles for article (PubMed ID: 32112088)
21. A variant erythroferrone disrupts iron homeostasis in
Bondu S; Alary AS; Lefèvre C; Houy A; Jung G; Lefebvre T; Rombaut D; Boussaid I; Bousta A; Guillonneau F; Perrier P; Alsafadi S; Wassef M; Margueron R; Rousseau A; Droin N; Cagnard N; Kaltenbach S; Winter S; Kubasch AS; Bouscary D; Santini V; Toma A; Hunault M; Stamatoullas A; Gyan E; Cluzeau T; Platzbecker U; Adès L; Puy H; Stern MH; Karim Z; Mayeux P; Nemeth E; Park S; Ganz T; Kautz L; Kosmider O; Fontenay M
Sci Transl Med; 2019 Jul; 11(500):. PubMed ID: 31292266
[TBL] [Abstract][Full Text] [Related]
22. The relation of SF3B1 mutation and intracellular iron in myelodysplastic syndrome with less than 5% bone marrow blasts.
Ma L; Luo Y; Jiang L; Shen D; Li J; Xu W; Mei C; Zhou X; Ren Y; Ye L; Lu C; Jie J; Tong H
Leuk Lymphoma; 2019 May; 60(5):1179-1186. PubMed ID: 30409066
[TBL] [Abstract][Full Text] [Related]
23. Co-mutation of
Song J; Moscinski L; Yang E; Shao H; Hussaini M; Zhang H
In Vivo; 2023; 37(3):985-993. PubMed ID: 37103105
[TBL] [Abstract][Full Text] [Related]
24. Clinical importance of SF3B1 mutations in Chinese with myelodysplastic syndromes with ring sideroblasts.
Cui R; Gale RP; Xu Z; Qin T; Fang L; Zhang H; Pan L; Zhang Y; Xiao Z
Leuk Res; 2012 Nov; 36(11):1428-33. PubMed ID: 22921018
[TBL] [Abstract][Full Text] [Related]
25. Splicing factor 3B subunit 1 (SF3B1) mutation in the context of therapy-related myelodysplastic syndromes.
Volpe VO; Al Ali N; Chan O; Padron E; Sallman DA; Kuykendall A; Sweet K; Lancet JE; Komrokji RS
Br J Haematol; 2022 Aug; 198(4):713-720. PubMed ID: 35751140
[TBL] [Abstract][Full Text] [Related]
26. Recent advances in the understanding of myelodysplastic syndromes with ring sideroblasts.
Malcovati L; Cazzola M
Br J Haematol; 2016 Sep; 174(6):847-58. PubMed ID: 27391606
[TBL] [Abstract][Full Text] [Related]
27. Clonal shifts in MDS - from SF3B1 to EZH2.
Barbosa Ribeiro A; Coucelo M; Tenreiro R; Simões AT; Marques G; Ribeiro L; Cortesão E; Sarmento-Ribeiro AB
Leuk Lymphoma; 2018 Dec; 59(12):2994-2997. PubMed ID: 29616853
[No Abstract] [Full Text] [Related]
28. Prognostic significance of SF3B1 mutations in patients with myelodysplastic syndromes: A meta-analysis.
Jafari PA; Sadeghian MH; Miri HH; Sadeghi R; Bagheri R; Lavasani S; Souri S
Crit Rev Oncol Hematol; 2020 Jan; 145():102832. PubMed ID: 31812130
[TBL] [Abstract][Full Text] [Related]
29. Altered splicing and cytoplasmic levels of tRNA synthetases in SF3B1-mutant myelodysplastic syndromes as a therapeutic vulnerability.
Liberante FG; Lappin K; Barros EM; Vohhodina J; Grebien F; Savage KI; Mills KI
Sci Rep; 2019 Feb; 9(1):2678. PubMed ID: 30804405
[TBL] [Abstract][Full Text] [Related]
30. [Features and clinical significance of gene mutations in patients with myelodysplastic syndromes with ring sideroblasts].
Cai YN; Xu ZF; Li B; Qin TJ; Pan LJ; Qu SQ; Hu NB; Liu D; Huang HJ; Shi ZX; Zhang YD; Xiao ZJ
Zhonghua Xue Ye Xue Za Zhi; 2020 May; 41(5):379-386. PubMed ID: 32536134
[No Abstract] [Full Text] [Related]
31. The Molecular Pathology of Myelodysplastic Syndrome.
Haferlach T
Pathobiology; 2019; 86(1):24-29. PubMed ID: 29791902
[TBL] [Abstract][Full Text] [Related]
32. Prognostic value of
Liang S; Zhou X; Pan H; Yang Y; Shi L; Wang L
Hematology; 2019 Dec; 24(1):613-622. PubMed ID: 31482762
[No Abstract] [Full Text] [Related]
33. Distinct bone marrow immunophenotypic features define the splicing factor 3B subunit 1 (SF3B1)-mutant myelodysplastic syndromes subtype.
Duetz C; Westers TM; In 't Hout FEM; Cremers EMP; Alhan C; Venniker-Punt B; Visser-Wisselaar HA; Chitu DA; de Graaf AO; Smit L; Jansen JH; van de Loosdrecht AA
Br J Haematol; 2021 May; 193(4):798-803. PubMed ID: 33765355
[TBL] [Abstract][Full Text] [Related]
34. Recurrent DNMT3A mutations in patients with myelodysplastic syndromes.
Walter MJ; Ding L; Shen D; Shao J; Grillot M; McLellan M; Fulton R; Schmidt H; Kalicki-Veizer J; O'Laughlin M; Kandoth C; Baty J; Westervelt P; DiPersio JF; Mardis ER; Wilson RK; Ley TJ; Graubert TA
Leukemia; 2011 Jul; 25(7):1153-8. PubMed ID: 21415852
[TBL] [Abstract][Full Text] [Related]
35. SF3B1 Mutations Negatively Predict for Response to Immunosuppressive Therapy in Myelodysplastic Syndromes.
Zhang Q; Haider M; Al Ali NH; Lancet JE; Epling-Burnette PK; List AF; Padron E; Komrokji RS
Clin Lymphoma Myeloma Leuk; 2020 Jun; 20(6):400-406.e2. PubMed ID: 32179032
[TBL] [Abstract][Full Text] [Related]
36. [Mutational analysis of RNA splicing machinery genes SF3B1, U2AF1 and SRSF2 in 118 patients with myelodysplastic syndromes and related diseases].
Wang JY; Ma J; Lin YN; Wang J; Shen H; Gui FM; Han C; Li QH; Song Z; Wang XJ
Zhonghua Xue Ye Xue Za Zhi; 2017 Mar; 38(3):192-197. PubMed ID: 28395441
[No Abstract] [Full Text] [Related]
37. Predicting survival in patients with myelodysplastic/myeloproliferative neoplasms with SF3B1 mutation and thrombocytosis.
Li F; Qin T; Li B; Qu S; Pan L; Zhang P; Sun Q; Cai W; Gao Q; Jiao M; Li J; Ai X; Ma J; Gale RP; Xu Z; Xiao Z
Leukemia; 2024 Jun; 38(6):1334-1341. PubMed ID: 38714876
[TBL] [Abstract][Full Text] [Related]
38. MDS with deletions in the long arm of chromosome 11 are associated with a high frequency of SF3B1 mutations.
Stengel A; Kern W; Meggendorfer M; Haferlach T; Haferlach C
Leukemia; 2017 Sep; 31(9):1995-1997. PubMed ID: 28592886
[No Abstract] [Full Text] [Related]
39. Does
Song J; Moscinski L; Zhang H; Zhang X; Hussaini M
Cancer Genomics Proteomics; 2019; 16(1):91-98. PubMed ID: 30587503
[TBL] [Abstract][Full Text] [Related]
40. Myelodysplastic Neoplasms (MDS) with Ring Sideroblasts or
Mortuza S; Chin-Yee B; James TE; Chin-Yee IH; Hedley BD; Ho JM; Saini L; Lazo-Langner A; Schenkel L; Bhai P; Sadikovic B; Keow J; Sangle N; Hsia CC
Curr Oncol; 2024 Mar; 31(4):1762-1773. PubMed ID: 38668037
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]